105752-11-2

Basic information

• Product Name: 4-IODO-PYRIDIN-3-YLAMINE
• Synonyms: 4-Iodopyridin-3-amine;3-amine-4-iodopyridin;3-Amnio-4-iodopyridine;4-Iodo-3-pyridinylamine;3-amine-4-iodopyridine;Zinc00334520;3-Pyridinamine, 4-iodo-;4-Iodo-3-pyridinamine
• CAS NO: 105752-11-2
• Molecular Formula: C₅H₅IN₂
• Molecular Weight: 220.01
• EINECS: -0
• Product Categories: Heterocycles;Pyridine;pyrdine series
• Mol File: 105752-11-2.mol

Chemical Properties

• Melting Point: 69.2-69.5°C
• Boiling Point: 327.2 °C at 760 mmHg
• Flash Point: 151.7 °C
• Appearance: tawny powder
• Density: 2.055
• Vapor Pressure: 0.000205mmHg at 25°C
• Refractive Index: 1.702
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.79±0.18(Predicted)
• Sensitive: Air & Light Sensitive
• CAS DataBase Reference: 4-IODO-PYRIDIN-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-IODO-PYRIDIN-3-YLAMINE(105752-11-2)
• EPA Substance Registry System: 4-IODO-PYRIDIN-3-YLAMINE(105752-11-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 105752-11-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-IODO-PYRIDIN-3-YLAMINE is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to serve as a building block in the development of new medications, particularly those targeting neurological and cardiovascular disorders.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-IODO-PYRIDIN-3-YLAMINE is utilized as a key component in the design and synthesis of novel compounds with potential therapeutic applications. Its reactivity and structural diversity make it a valuable tool for researchers in drug discovery and development.
Used in Chemical Synthesis:
4-IODO-PYRIDIN-3-YLAMINE is also employed in chemical synthesis processes, where it can be used to produce a range of other heterocyclic compounds with diverse applications. Its versatility in chemical reactions makes it a valuable starting material for the synthesis of various organic molecules.

InChI:InChI=1/C5H5IN2/c6-4-1-2-8-3-5(4)7/h1-3H,7H2

Upstream product

• 239137-39-4 3-amino-4-bromopyridine 
• 70298-88-3 N-(pyridin-3-yl)pivalamide 
• 462-08-8 pyridin-3-ylamine 
• 113975-32-9 2,2-dimethyl-N-(4-iodo-3-pyridinyl)propanamide 

Downstream Products

• 25797-08-4 2,3-diphenyl-1H-pyrrolo[2,3-c]pyridine 
• 449173-38-0 3-amino-4-(2-phenylethynyl)pyridine 
• 654077-74-4 benzylidene(4-iodopyridin-3-yl)amine 
• 25796-97-8 2,3-dimethyl-1H-pyrrolo[2,3-c]pyridine 
• 1049768-77-5 C₁₉H₃₀N₂Si 
• 885272-20-8 3,4-dihydro-1H-1,7-naphthyridin-2-one 
• 18504-86-4 2H-pyrido<4,3-b><1,4>thiazin-3(4H)-one 
• 1052705-85-7 4-(cyclohex-1-en-1-yl)pyridin-3-amine 
• 2922-07-8 2-phenyl-1H-pyrrolo[2,3-c]pyridine 
• 945608-00-4 2-phenylpyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of optically active ring-A substituted tryptophans as IDO inhibitors

The first synthesis of optically active 7-methoxy-d-tryptophan as well as other ring-A substituted tryptophans is described.

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS

This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS

This invention relates to novel 3-aminopyridines of the formula (I) wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

Light-driven coordination-induced spin-state switching: Rational design of photodissociable ligands

The bistability of spin states (e.g., spin crossover) in bulk materials is well investigated and understood. We recently extended spin-state switching to isolated molecules at room temperature (light-driven coordination-induced spin-state switching, or LD-CISSS). Whereas bistability and hysteresis in conventional spin-crossover materials are caused by cooperative effects in the crystal lattice, spin switching in LD-CISSS is achieved by reversibly changing the coordination number of a metal complex by means of a photochromic ligand that binds in one configuration but dissociates in the other form. We present mathematical proof that the maximum efficiency in property switching by such a photodissociable ligand (PDL) is only dependent on the ratio of the association constants of both configurations. Rational design by using DFT calculations was applied to develop a photoswitchable ligand with a high switching efficiency. The starting point was a nickel-porphyrin as the transition-metal complex and 3-phenylazopyridine as the photodissociable ligand. Calculations and experiments were performed in two iterative steps to find a substitution pattern at the phenylazopyridine ligand that provided optimum performance. Following this strategy, we synthesized an improved photodissociable ligand that binds to the Ni-porphyrin with an association constant that is 5.36times higher in its trans form than in the cis form. The switching efficiency between the diamagnetic and paramagnetic state is efficient as well (72 % paramagnetic Ni-porphyrin after irradiation at 365nm, 32 % paramagnetic species after irradiation at 440nm). Potential applications arise from the fact that the LD-CISSS approach for the first time allows reversible switching of the magnetic susceptibility of a homogeneous solution. Photoswitchable contrast agents for magnetic resonance imaging and light-controlled magnetic levitation are conceivable applications. Turn the spin: Nickel-porphyrins with appropriately designed axial photochromic ligands change their coordination number and consequently their spin state reversibly upon irradiation. Rational design led to a substituted 3-phenylazopyridine as a photodissociable ligand with a switching efficiency of 40 % (see figure). Thus, the magnetic susceptibility of a homogeneous solution was switched by a factor of more than two at room temperature.

The first porous MOF with photoswitchable linker molecules

We synthesized a porous twofold interpenetrated MOF [Zn2(NDC) 2(1)] (coined CAU-5) using 3-azo-phenyl-4,4′-bipyridine (1), 2,6-naphthalenedicarboxylic acid, and Zn(NO3)2· 6H2O. The azo-functionality protrudes into the pores, and can be switched, by irradiation with UV light (365 nm), from the thermodynamically stable trans-isomer to the cis-isomer. Back-switching was achieved thermally and with an irradiation wavelength of λmax = 440 nm.

AZA-BETA-CARBOLINES AND METHODS OF USING SAME

Provided are compounds having the general structure according to Formula (I): Further provided are pharmaceutical compositions comprising these compounds. The invention still further provides methods of treating alcoholism, methods of reducing alcohol intake, methods of treating anhedonia, and methods of treating anxiety using theses compounds or the compositions containing them.

Aza-Tryptamine Substrates in Monoterpene Indole Alkaloid Biosynthesis

Biosynthetic pathways can be hijacked to yield novel compounds by introduction of novel starting materials. Here we have altered tryptamine, which serves as the starting substrate for a variety of alkaloid biosynthetic pathways, by replacing the indole with one of four aza-indole isomers. We show that two aza-tryptamine substrates can be successfully incorporated into the products of the monoterpene indole alkaloid pathway in Catharanthus roseus. Use of unnatural heterocycles in precursor-directed biosynthesis, in both microbial and plant natural product pathways, has not been widely demonstrated, and successful incorporation of starting substrate analogs containing the aza-indole functionality has not been previously reported. This work serves as a starting point to explore fermentation of aza-alkaloids from other tryptophan- and tryptamine-derived natural product pathways.

Nonsteroidal glucocorticoid agonists: Tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (Transrepression/Transactivation) efficacy selectivity

The synthesis and biological activity of tetrahydronaphthalene derivatives coupled to various heterocycles are described. These compounds are potent glucocorticoid receptor agonists with efficacy selectivity in an NFκB glucocorticoid receptor (GR) agonist assay (representing transrepression effects) over an MMTV GR agonist assay (representing transactivation effects). Quinolones, indoles, and C- and N-linked quinolines are some of the heterocycles that provide efficacy selectivity. For example, the isoquinoline 49D1E2 has NFκB agonism with pIC50 of 8.66 (89%) and reduced efficacy in MMTV agonism (6%), and the quinoline 55D1E1 has NFκB agonism with pIC 50 of 9.30 (101%) and reduced efficacy in MMTV agonism with pEC 50 of 8.02 (47%). A description of how a compound from each class is modeled in the active site of the receptor is given.

INHIBITORS OF TRYPTASE

The present invention related to certain inhibitors of tryptase that are inhibitors of tryptase, pharmaceutical composition comprising these compounds and method of treating asthma, allergic rhinitis, and/or Chronic Obstructive Pulmonary Disease utilizing these compounds.

Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands

The invention relates to tetrahydronaphthyridine derivatives having formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said tetrahydronaphthyridine derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.